{"id":9199,"date":"2018-09-18T12:09:07","date_gmt":"2018-09-18T12:09:07","guid":{"rendered":"http:\/\/fefac.cat\/empresarial\/?p=9199"},"modified":"2018-09-18T12:09:07","modified_gmt":"2018-09-18T12:09:07","slug":"el-teu-farmacutic-tinforma-leucmia-limftica-c","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/","title":{"rendered":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC)"},"content":{"rendered":"<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\">La LLC &eacute;s un <strong>c&agrave;ncer de la sang de creixement lent amb origen en els limf&ograve;cits B<\/strong>, un tipus de gl&ograve;bul blanc o leuc&ograve;cit. Els limf&ograve;cits B formen part del sistema immunol&ograve;gic i tenen un paper important per combatre les infeccions de l&rsquo;organisme. La LLC &eacute;s el resultat d&rsquo;un proc&eacute;s maduratiu anormal i un mal funcionament de limf&ograve;cits B, que es reprodueixen de forma an&ograve;mala. En els limf&ograve;cits B malignes no funcionen correctament les vies de senyalitzaci&oacute; cel&middot;lular que controlen la proliferaci&oacute;, l&rsquo;adher&egrave;ncia, la migraci&oacute; i la superviv&egrave;ncia de les c&egrave;l&middot;lules. Aquesta desregulaci&oacute; fa que els limf&ograve;cits de la LLC es desplacin i romanguin en entorns protectors com la medul&middot;la &ograve;ssia i els ganglis limf&agrave;tics, on s&rsquo;acumulen en gran nombre en proliferar lliurement.<\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>PREVALEN&Ccedil;A I PACIENTS<\/strong><\/p>\n<ul>\n<li style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\">La taxa d&rsquo;incid&egrave;ncia aproximada al m&oacute;n occidental &eacute;s de <strong>4 casos cada 100.000 persones.<\/strong><\/li>\n<li style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\">&Eacute;s m&eacute;s freq&uuml;ent en homes i la mitjana d&rsquo;edat al diagn&ograve;stic &eacute;s de <strong>73 anys. <\/strong><\/li>\n<li style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>El 78% dels pacients amb LLC sobreviuran 5 anys despr&eacute;s<\/strong> del diagn&ograve;stic.<\/li>\n<\/ul>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>PRON&Ograve;STIC<\/strong><\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\">La LLC &eacute;s una malaltia cr&ograve;nica i incurable per&ograve; de curs generalment molt indolent, de manera que molts pacients no requeriran mai tractament i moriran per altres causes. En cas de requerir tractament, s&rsquo;han realitzat molts avan&ccedil;os en els &uacute;ltims anys i es disposa de diverses opcions que van des de la quimioter&agrave;pia convencional a nous f&agrave;rmacs inhibidors de BCR i BCL-2 que s&oacute;n d&rsquo;administraci&oacute; oral.<\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>Informa el teu pacient<\/strong><\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>Les farm&agrave;cies de Catalunya han comen&ccedil;at a rebre d&iacute;ptics per informar els pacients amb leuc&egrave;mia limf&agrave;tica cr&ograve;nica (LLC)<\/strong>, gr&agrave;cies a la campanya de salut iniciada per la Federaci&oacute; d&rsquo;Associacions de Farm&agrave;cies de Catalunya (<strong>FEFAC<\/strong>) i la Fundaci&oacute; Lliga Catalana d&rsquo;Ajuda Oncol&ograve;gica (<strong>Oncolliga<\/strong>), que ha distribu&iuml;t, gr&agrave;cies a<strong>&nbsp;Alliance Healthcare<\/strong>&nbsp;aquest material a les farm&agrave;cies catalanes. El d&iacute;ptic ha estat elaborat amb el suport de la companyia&nbsp;<strong>Janssen<\/strong>.&nbsp;<\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>22 de setembre, Dia Mundial de la Leuc&egrave;mia Limf&agrave;tica Cr&ograve;nica (LLC).<\/strong><\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\">El 22 de setembre es commemora&nbsp;el<strong>&nbsp;Dia de la Leuc&egrave;mia Limf&agrave;tica Cr&ograve;nica<\/strong>, aix&iacute; que les setmanes pr&egrave;vies s&oacute;n una oportunitat per informar a la societat sobre aquesta malaltia, i els d&iacute;ptics d&rsquo;Oncolliga, una eina per fer-ho. La implicaci&oacute; dels farmac&egrave;utics &eacute;s imprescindible i, per aquest motiu, et demanem que et sumis a la campanya.<\/p>\n<p style=\"font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px;\"><strong>Si tens cap mena de dubte o necessites m&eacute;s informaci&oacute;, pots posar-te en contacte amb l&rsquo;equip de FEFAC (93 323 24 22).<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La LLC &eacute;s un c&agrave;ncer de la sang de creixement lent amb origen en els limf&ograve;cits B, un tipus de gl&ograve;bul blanc o leuc&ograve;cit. Els limf&ograve;cits B formen part del [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[18,11,12,13,14,15],"tags":[579,711,1079,1127,1808,1809],"class_list":["post-9199","post","type-post","status-publish","format-standard","hentry","category-general","category-fefac","category-afb","category-afet","category-afell","category-agfe","tag-cancer","tag-farmaceutics","tag-dies-mundials","tag-farmacia","tag-llc","tag-leucemia-limfatica-cronica"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC\" \/>\n<meta property=\"og:description\" content=\"La LLC &eacute;s un c&agrave;ncer de la sang de creixement lent amb origen en els limf&ograve;cits B, un tipus de gl&ograve;bul blanc o leuc&ograve;cit. Els limf&ograve;cits B formen part del [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-18T12:09:07+00:00\" \/>\n<meta name=\"author\" content=\"qabh859\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"qabh859\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/\"},\"author\":{\"name\":\"qabh859\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\"},\"headline\":\"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC)\",\"datePublished\":\"2018-09-18T12:09:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/\"},\"wordCount\":557,\"keywords\":[\"c\u00e0ncer\",\"farmac\u00e8utics\",\"dies mundials\",\"farm\u00e0cia\",\"LLC\",\"leuc\u00e8mia limf\u00e0tica cr\u00f2nica\"],\"articleSection\":[\"General\",\"FEFAC\",\"AFB\",\"AFET\",\"AFELL\",\"AGFE\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/\",\"name\":\"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"datePublished\":\"2018-09-18T12:09:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/el-teu-farmacutic-tinforma-leucmia-limftica-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/03012b2506772bd65738ce781a3947f7\",\"name\":\"qabh859\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/qabh859\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/","og_locale":"ca_ES","og_type":"article","og_title":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC","og_description":"La LLC &eacute;s un c&agrave;ncer de la sang de creixement lent amb origen en els limf&ograve;cits B, un tipus de gl&ograve;bul blanc o leuc&ograve;cit. Els limf&ograve;cits B formen part del [&hellip;]","og_url":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/","og_site_name":"FEFAC","article_published_time":"2018-09-18T12:09:07+00:00","author":"qabh859","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"qabh859","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/"},"author":{"name":"qabh859","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7"},"headline":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC)","datePublished":"2018-09-18T12:09:07+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/"},"wordCount":557,"keywords":["c\u00e0ncer","farmac\u00e8utics","dies mundials","farm\u00e0cia","LLC","leuc\u00e8mia limf\u00e0tica cr\u00f2nica"],"articleSection":["General","FEFAC","AFB","AFET","AFELL","AGFE"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/","url":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/","name":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC) - FEFAC","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"datePublished":"2018-09-18T12:09:07+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7"},"breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/el-teu-farmacutic-tinforma-leucmia-limftica-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"El teu farmac\u00e8utic t\u2019informa: leuc\u00e8mia limf\u00e0tica cr\u00f2nica (LLC)"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/03012b2506772bd65738ce781a3947f7","name":"qabh859","url":"https:\/\/fefac.cat\/empresarial\/author\/qabh859\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/9199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=9199"}],"version-history":[{"count":0,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/9199\/revisions"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=9199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=9199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=9199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}